48,830
edits
Line 4: | Line 4: | ||
*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | *Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | ||
**Testing done together with ALK. | **Testing done together with ALK. | ||
*EGRF mutation excludes ALK rearrangement.<ref name=pmid23729361>{{Cite journal | last1 = Gainor | first1 = JF. | last2 = Varghese | first2 = AM. | last3 = Ou | first3 = SH. | last4 = Kabraji | first4 = S. | last5 = Awad | first5 = MM. | last6 = Katayama | first6 = R. | last7 = Pawlak | first7 = A. | last8 = Mino-Kenudson | first8 = M. | last9 = Yeap | first9 = BY. | title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. | journal = Clin Cancer Res | volume = 19 | issue = 15 | pages = 4273-81 | month = Aug | year = 2013 | doi = 10.1158/1078-0432.CCR-13-0318 | PMID = 23729361 }}</ref> | |||
===Associations=== | ===Associations=== |
edits